Your browser doesn't support javascript.
loading
Liquid biopsy epigenomic profiling for cancer subtyping.
Baca, Sylvan C; Seo, Ji-Heui; Davidsohn, Matthew P; Fortunato, Brad; Semaan, Karl; Sotudian, Shahabbedin; Lakshminarayanan, Gitanjali; Diossy, Miklos; Qiu, Xintao; El Zarif, Talal; Savignano, Hunter; Canniff, John; Madueke, Ikenna; Saliby, Renee Maria; Zhang, Ziwei; Li, Rong; Jiang, Yijia; Taing, Len; Awad, Mark; Chau, Cindy H; DeCaprio, James A; Figg, William D; Greten, Tim F; Hata, Aaron N; Hodi, F Stephen; Hughes, Melissa E; Ligon, Keith L; Lin, Nancy; Ng, Kimmie; Oser, Matthew G; Meador, Catherine; Parsons, Heather A; Pomerantz, Mark M; Rajan, Arun; Ritz, Jerome; Thakuria, Manisha; Tolaney, Sara M; Wen, Patrick Y; Long, Henry; Berchuck, Jacob E; Szallasi, Zoltan; Choueiri, Toni K; Freedman, Matthew L.
Affiliation
  • Baca SC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Seo JH; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Davidsohn MP; Eli and Edythe L. Broad Institute, Cambridge, MA, USA.
  • Fortunato B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Semaan K; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Sotudian S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Lakshminarayanan G; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Diossy M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Qiu X; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
  • El Zarif T; Eli and Edythe L. Broad Institute, Cambridge, MA, USA.
  • Savignano H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Canniff J; Eli and Edythe L. Broad Institute, Cambridge, MA, USA.
  • Madueke I; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Saliby RM; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Zhang Z; Eli and Edythe L. Broad Institute, Cambridge, MA, USA.
  • Li R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Jiang Y; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Taing L; Computational Health Informatics Program, Boston Children's Hospital, Boston, MA, USA.
  • Awad M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Chau CH; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
  • DeCaprio JA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Figg WD; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Greten TF; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Hata AN; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Hodi FS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Hughes ME; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Ligon KL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Lin N; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Ng K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Oser MG; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Meador C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Parsons HA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Pomerantz MM; Eli and Edythe L. Broad Institute, Cambridge, MA, USA.
  • Rajan A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Ritz J; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Thakuria M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Tolaney SM; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Wen PY; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Long H; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Berchuck JE; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Szallasi Z; Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Choueiri TK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Freedman ML; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Nat Med ; 29(11): 2737-2741, 2023 Nov.
Article in En | MEDLINE | ID: mdl-37865722
ABSTRACT
Although circulating tumor DNA (ctDNA) assays are increasingly used to inform clinical decisions in cancer care, they have limited ability to identify the transcriptional programs that govern cancer phenotypes and their dynamic changes during the course of disease. To address these limitations, we developed a method for comprehensive epigenomic profiling of cancer from 1 ml of patient plasma. Using an immunoprecipitation-based approach targeting histone modifications and DNA methylation, we measured 1,268 epigenomic profiles in plasma from 433 individuals with one of 15 cancers. Our assay provided a robust proxy for transcriptional activity, allowing us to infer the expression levels of diagnostic markers and drug targets, measure the activity of therapeutically targetable transcription factors and detect epigenetic mechanisms of resistance. This proof-of-concept study in advanced cancers shows how plasma epigenomic profiling has the potential to unlock clinically actionable information that is currently accessible only via direct tissue sampling.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Circulating Tumor DNA / Neoplasms Limits: Humans Language: En Journal: Nat Med Journal subject: BIOLOGIA MOLECULAR / MEDICINA Year: 2023 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Circulating Tumor DNA / Neoplasms Limits: Humans Language: En Journal: Nat Med Journal subject: BIOLOGIA MOLECULAR / MEDICINA Year: 2023 Type: Article Affiliation country: United States